Alnylam Pharmaceuticals, INC

Alnylam Pharmaceuticals reported strong Q2 2026 results with significant revenue growth, but revised its full-year TTR net product revenue guidance downwards.

Alnylam Pharmaceuticals announced first quarter 2026 financial results, achieving over $1 billion in quarterly product revenues for the first time, driven by significant growth in TTR therapies.

Alnylam Pharmaceuticals' Board of Directors has granted CEO Yvonne Greenstreet a special performance-based equity award to incentivize future growth and leadership through 2029.

Alnylam Pharmaceuticals reported robust fourth quarter and full year 2025 financial results, achieving GAAP and non-GAAP profitability driven by significant AMVUTTRA sales and outlining ambitious 2026 pipeline goals.

Alnylam Pharmaceuticals announced its ambitious Alnylam 2030 strategy, alongside preliminary full-year 2025 net product revenues of $2,987 million and robust 2026 revenue guidance.

Alnylam Pharmaceuticals announced a partial repurchase of its 1.00% Convertible Senior Notes due 2027 for approximately $51.9 million in cash.

Alnylam Pharmaceuticals announced robust Q2 2026 results, driven by significant growth in AMVUTTRA sales and increased royalty revenue.

Alnylam Pharmaceuticals announced a significant increase in total revenues, driven by strong product sales, particularly AMVUTTRA, and improved operational income.

Alnylam Pharmaceuticals reported a significant increase in total revenues and net income for the third quarter and first nine months of 2025, driven by robust AMVUTTRA sales and a major milestone payment from Roche for zilebesiran.

Alnylam Pharmaceuticals announced significant increases in product revenue, driven by AMVUTTRA's expanded indications, but reported a widening net loss and faced adverse rulings in key patent infringement lawsuits.

Alnylam Pharmaceuticals reports increased net product revenues and collaboration revenues in Q1 2025, driven by AMVUTTRA and strategic partnerships.

Alnylam Pharmaceuticals reports a net loss for the third quarter of 2024, despite a 34% increase in net product revenues, driven by growth in AMVUTTRA sales.

Alnylam Pharmaceuticals reports its first profitable fiscal year in 2025, fueled by robust sales of AMVUTTRA and strategic pipeline advancements.

Alnylam Pharmaceuticals highlights advancements in its RNAi therapeutics pipeline and commercial performance in its 2024 annual report, aiming for self-sustainability by the end of 2025.

Alnylam Pharmaceuticals' 2023 10-K filing highlights its transition to a top-tier biotech company, marked by revenue growth, pipeline advancements, and strategic collaborations.

Alnylam Pharmaceuticals Director David E.I. Pyott executed a series of stock transactions under a pre-arranged Rule 10b5-1(c) trading plan.

Alnylam Pharmaceuticals director Benjamin Cravatt acquired stock options valued at $295.63 per share, with vesting over three years.

Director Charles Elliott Sigal acquired 671 restricted stock units and 1,441 stock options as part of an annual equity incentive grant.

Director Amy W. Schulman was granted 838 restricted stock units and 1,802 stock options as part of annual compensation.

Director Colleen F. Reitan was granted 671 restricted stock units and 1,441 stock options as part of Alnylam Pharmaceuticals' incentive plan.

Alnylam Pharmaceuticals Director David E.I. Pyott acquired 671 restricted stock units and 1,441 stock options as part of an annual equity grant.

Alnylam Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 20, 2026, to elect directors, approve executive compensation, and ratify auditors.

Alnylam Pharmaceuticals files an amendment to its proxy statement to clarify the voting requirements for a proposal regarding officer exculpation.

Alnylam Pharmaceuticals announces its 2025 Annual Meeting of Stockholders, urging shareholders to vote on key proposals including the election of directors, approval of an amendment to the Restated Certificate of Incorporation, approval of the second amended and restated 2018 Stock Incentive Plan, an advisory vote on executive compensation, and ratification of the appointment of PricewaterhouseCoopers LLP as independent auditors.

Alnylam Pharmaceuticals is set to hold its 2025 Annual Meeting of Stockholders virtually on May 8, 2025, with proposals including director elections, charter amendments, and executive compensation.

Alnylam Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on May 16, 2024, with voting open until May 15, 2024.

Alnylam Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on May 16, 2024, covering director elections, executive compensation, and auditor ratification.

Capital World Investors has disclosed a beneficial ownership of 10,916,799 shares, representing 8.2% of the outstanding common stock of Alnylam Pharmaceuticals, Inc.

FMR LLC, through its affiliates, has reported beneficial ownership of 11.0% of Alnylam Pharmaceuticals' common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.35% of Alnylam Pharmaceuticals' common stock as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Alnylam Pharmaceuticals Inc. common stock following an internal realignment on January 12, 2026.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.8% beneficial ownership stake in Alnylam Pharmaceuticals Inc. as of September 30, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.03% beneficial ownership stake in Alnylam Pharmaceuticals Inc. as of March 31, 2025.